Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Amphastar Pharmaceuticals Inc before investing.

In this article, we go over a few key elements for understanding Amphastar Pharmaceuticals Inc’s stock price such as:

• Amphastar Pharmaceuticals Inc’s current stock price and volume
• Why Amphastar Pharmaceuticals Inc’s stock price changed recently
• Upgrades and downgrades for AMPH from analysts
• AMPH’s stock price momentum as measured by its relative strength

About Amphastar Pharmaceuticals Inc (AMPH)

Before we jump into Amphastar Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. It operates through two segments: finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Primatene Mist is an epinephrine inhalation product, which is indicated for the temporary relief of mild symptoms of intermittent asthma. Its portfolio also includes BAQSIMI (BAK-see-mee), which is used to treat very low blood sugar in people with diabetes ages 4 years and above.

Want to learn more about Amphastar Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc’s Stock Price as of Market Close

As of November 09, 2023, 4:00 PM, CST, Amphastar Pharmaceuticals Inc’s stock price was $52.41.

Amphastar Pharmaceuticals Inc is up 15.39% from its previous closing price of $45.42.

During the last market session, Amphastar Pharmaceuticals Inc’s stock traded between $44.43 and $46.66. Currently, there are 48.40 million shares of Amphastar Pharmaceuticals Inc stock available for purchase.

Amphastar Pharmaceuticals Inc’s price-earnings (P/E) ratio is currently at 23.3, which is high compared to the Pharmaceuticals industry median of 20.2. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Amphastar Pharmaceuticals Inc Stock Price History

Amphastar Pharmaceuticals Inc’s (AMPH) price is currently up 15.77% so far this month.

During the month of November, Amphastar Pharmaceuticals Inc’s stock price has reached a high of $52.73 and a low of $44.43.

Over the last year, Amphastar Pharmaceuticals Inc has hit prices as high as $67.66 and as low as $27.00. Year to date, Amphastar Pharmaceuticals Inc’s stock is up 125.03%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Amphastar Pharmaceuticals Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 08, 2023, there was 1 analyst who downgraded Amphastar Pharmaceuticals Inc’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Amphastar Pharmaceuticals Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Amphastar Pharmaceuticals Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Amphastar Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Amphastar Pharmaceuticals Inc (AMPH) by visiting AAII Stock Evaluator.

Relative Price Strength of Amphastar Pharmaceuticals Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 08, 2023, Amphastar Pharmaceuticals Inc has a weighted four-quarter relative price strength of 6.00%, which translates to a Momentum Score of 86 and is considered to be Very Strong.

Want to learn more about how Amphastar Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Amphastar Pharmaceuticals Inc Stock Price: Bottom Line

As of November 9, 2023, Amphastar Pharmaceuticals Inc’s stock price is $52.41, which is up 15.39% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Amphastar Pharmaceuticals Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.